Literature DB >> 10797605

Correction for age of anticardiolipin antibodies cut-off points.

E Rapizzi1, A Ruffatti, M Tonello, A Piccoli, A Calligaro, P Sfriso, S Todesco.   

Abstract

Immunoglobulin (Ig) isotypes G, M, and A of anticardiolipin antibodies (aCL) are considered markers of antiphospholipid syndrome (APS). They were determined by ELISA in sera of 100 healthy children aged between 6 months and 16 yrs (mean 5.4 yrs +/-3.4 SD) and 100 healthy elderly subjects aged between 65 and 103 yrs (mean 84.2 yrs +/-8.1 SD). The frequency with which they were detected was compared to that in sera of 100 healthy adults aged between 21 and 47 yrs (mean 25.8 yrs +/-5.2 SD) in order to evaluate if adult aCL cut-off levels were fit for pediatric and elderly populations. The cut-off points were calculated adding 2.5 SD to the mean values and, in the adult group, the results were 11.6 GPL, 7.5 MPL, and 23.9 APL for IgG, IgM, and IgA, respectively. In the children, IgG aCL were positive in 26 cases (26%), IgM and IgA aCL in 1 case (1%) respectively. Statistical comparison of these results to those of adults showed a higher significant frequency for children IgG aCL (P = 0.0001) with the major contribution by children aged between 6 months and 5 yrs, and a lower significant frequency for children IgA aCL (P = 0.041). In elderly subjects IgG aCL were positive in 12 cases (12%), IgM aCL in 4 (4%), and IgA aCL in 37 (37%). In a comparison of these values to those of adults, only elderly IgA aCL frequency was significantly higher (P = 0.0001) with the major contribution by the oldest subgroup. In order to avoid false positive results for IgG aCL in children and for IgA aCL in elderly, as well as false negative results for IgA aCL in children, we introduced three new cut-off points: (1) 27.7 GPL for IgG aCL in children; (2) 13.8 APL for IgA aCL in children; and (3) 51.1 APL for IgA aCL in elderly subjects. These data suggest that a correction for age of aCL cut-off levels should be considered to raise specificity and sensitivity for APS in pediatric as well as in elderly populations. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10797605      PMCID: PMC6808055     

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  19 in total

1.  Antiphospholipid syndrome in a child with trisomy 21: the relationship between anticardiolipin G antibodies and the von Willebrand factor.

Authors:  G Guariso; A Ruffatti; A Casonato; P Drigo; A Ghirardello; L Zancan
Journal:  Clin Exp Rheumatol       Date:  1992 Nov-Dec       Impact factor: 4.473

2.  Anti-double-stranded DNA antibodies in the healthy elderly: prevalence and characteristics.

Authors:  A Ruffatti; A Calligaro; T Del Ross; M T Bertoli; A Doria; L Rossi; S Todesco
Journal:  J Clin Immunol       Date:  1990-11       Impact factor: 8.317

Review 3.  Clinical manifestations and management of the antiphospholipid syndrome.

Authors:  R H Derksen
Journal:  Lupus       Date:  1996-04       Impact factor: 2.911

4.  Longitudinal changes in serum immunoglobulin levels in older humans.

Authors:  C E Buckley; E G Buckley; F C Dorsey
Journal:  Fed Proc       Date:  1974-09

5.  Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. The Antiphospholipid Antibodies in Stroke Study Group.

Authors: 
Journal:  Stroke       Date:  1990-09       Impact factor: 7.914

6.  A catastrophic antiphospholipid syndrome: the importance of high levels of warfarin anticoagulation.

Authors:  A Ruffatti; G De Silvestro; A Ghirardello; A Calligaro; T Del Ross; G Thiene; S Todesco
Journal:  J Intern Med       Date:  1994-01       Impact factor: 8.989

Review 7.  Stroke prevention in patients with antiphospholipid antibodies.

Authors:  R L Brey
Journal:  Lupus       Date:  1994-08       Impact factor: 2.911

8.  Admission criteria for immunogerontological studies in man: the SENIEUR protocol.

Authors:  G J Ligthart; J X Corberand; C Fournier; P Galanaud; W Hijmans; B Kennes; H K Müller-Hermelink; G G Steinmann
Journal:  Mech Ageing Dev       Date:  1984-11       Impact factor: 5.432

9.  Systemic lupus erythematosus and lymphoma: association with antiphospholipid syndrome.

Authors:  R A Asherson; S Block; F A Houssiau; G R Hughes
Journal:  J Rheumatol       Date:  1991-02       Impact factor: 4.666

10.  High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population.

Authors:  M N Manoussakis; A G Tzioufas; M P Silis; P J Pange; J Goudevenos; H M Moutsopoulos
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

View more
  5 in total

Review 1.  Pediatric antiphospholipid syndrome.

Authors:  Cassyanne L Aguiar; Arzu Soybilgic; Tadej Avcin; Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

Review 2.  Pediatric antiphospholipid syndrome.

Authors:  Jacqueline A Madison; Yu Zuo; Jason S Knight
Journal:  Eur J Rheumatol       Date:  2019-12-03

Review 3.  Update on antiphospholipid syndrome in children.

Authors:  Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 4.  Antiphospholipid antibodies in pediatrics.

Authors:  Ana I Quintero-Del-Rio
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

Review 5.  Epidemiology of Antiphospholipid Syndrome in the General Population.

Authors:  Jesse Y Dabit; Maria O Valenzuela-Almada; Sebastian Vallejo-Ramos; Alí Duarte-García
Journal:  Curr Rheumatol Rep       Date:  2022-01-05       Impact factor: 4.592

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.